Gutiérrez-Gutiérrez, BRodríguez-Baño, J2023-01-252023-01-252019-04-12http://hdl.handle.net/10668/13828Extended-spectrum β-lactamase-producing Enterobacteriaceae (ESBL-E) are a frequent cause of invasive infections worldwide. Carbapenems are nowadays the most used drugs to treat these infections. However, due to the increasing rates of resistance to these antimicrobials, carbapenem-sparing alternatives are being investigated. The aim of this narrative literature review is to summarize the published information on the currently available antibiotics for the treatment of ESBL-E infections, providing specific information on three subgroups of patients: Group 1, patients with severe infections or infections from high-risk sources or in severely immunocompromised patients; Group 2, patients with non-severe infections from intermediate-risk source; and Group 3, patients with non-severe urinary tract infection. For patients in Group 1, the current data would support the use of carbapenems. For milder infections, however, particularly urinary tract infections, other non-carbapenem antibiotics can be considered in selected cases, including beta-lactam/beta-lactam inhibitor combinations, cephamycins, temocillin and aminoglycosides. While specific studies should be performed in these situations, individualized decisions may be taken in order to avoid overuse of carbapenems.enBloodstream infectionsCarbapenemsExtended-spectrum beta-lactamasesMortalityTreatmentUrinary tract InfectionsAnti-Bacterial AgentsCarbapenemsEnterobacteriaceaeEnterobacteriaceae InfectionsHumansImmunocompromised HostRandomized Controlled Trials as TopicUrinary Tract Infectionsbeta-Lactamase Inhibitorsbeta-Lactamasesresearch article30986558open access10.1016/j.cmi.2019.03.0301469-0691http://www.clinicalmicrobiologyandinfection.com/article/S1198743X19301557/pdf